Gene V. Wallenstein - Concepedia

Author

Gene V. Wallenstein

Also Known As

G V Wallenstein, G. V. Wallenstein, G. Wallenstein, G.V. Wallenstein, GENE V. WALLENSTEIN, GENE WALLENSTEIN, Gene V Wallenstein, Gene V. Wallenstein, Gene Wallenstein, Wallenstein, G.

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Metroplex Clinical Research Center Stanford University Albany Medical Center Hospital Seoul National University

About

Gene V. Wallenstein is an author at Pfizer (United States) specializing in neuroscience, social sciences, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Social Sciences	9	9	630
2	Medicine	8	8	1.7K
3	Cognitive Science	4	4	458
4	Health Sciences	2	2	153
5	Behavioral Sciences	1	1	77

Gene V. Wallenstein

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Roy Fleischmann, Joel M. Kremer, John J. Cush, New England Journal of Medicine	2012	1K
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, New England Journal of Medicine	2012	922
Tofacitinib versus Methotrexate in Rheumatoid Arthritis Eun Bong Lee, Roy Fleischmann, Stephen Hall, New England Journal of Medicine	2014	761
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryMedicine	2013	714
Gamma Frequency–Range Abnormalities to Auditory Stimulation in Schizophrenia Jun Soo Kwon, Brian F. O’Donnell, Gene V. Wallenstein, Archives of General Psychiatry	1999	656
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Arthritis & Rheumatism	2013	572
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Joel M. Kremer, Zhanguo Li, Stephen Hall, Annals of Internal Medicine ImmunologyPharmacotherapyInflammatory ArthritisInflammationRheumatoid Disorder	2013	441
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Arthritis & Rheumatism	2011	376
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Arthritis & Rheumatism	2011	343
GABAergic Modulation of Hippocampal Population Activity: Sequence Learning, Place Field Development, and the Phase Precession Effect Gene V. Wallenstein, Michael E. Hasselmo Journal of Neurophysiology Gabaergic ModulationDevelopmental Cognitive NeurosciencePeriodic GabaNeurotransmissionBrain Organization	1997	299

Page 1